Oncology professionals from around the world are in Chicago for the ASCO Annual Meeting. There, they will discuss the latest advances and newest thoughts in cancer research. Some of those advances focus on improving the quality of care and patients’ access to it.
These studies from the ASCO Annual Meeting show some of the newest thoughts and latest advances in using immunotherapy and targeted therapy to treat bladder, stomach, and lung cancers.
Patient advocate Dusty Donaldson reports from the 2016 Cancer Survivorship Symposium and discusses the growing support for survivorship care plans for all people with cancer.
What is low dose CT screening for lung cancer? What are the benefits and risks? Should I ask my doctor about it? In this podcast, Dr. Bernardo Goulart answers these questions and more.
Immunotherapy is one of the hottest topics in cancer research. This year, focus at the ASCO Annual Meeting has been on a type of immunotherapy called PD-1 inhibitors. Learn how these drugs may help improve the treatment of head and neck, liver, and lung cancers.
In this podcast, experts discuss ASCO’s recent endorsement of ASTRO’s guideline for radiation therapy for non-small cell lung cancer.
Dr. Julie Brahmer from the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins shares details about the recent FDA approval of nivolumab (Opdivo) for advanced non-small cell lung cancer. She explains how this impacts the treatment of lung cancer.
This weekend, Dr. Jyoti Patel will be running the Chicago Marathon to celebrate all of those with advanced lung cancer who are here “10 years strong.” During her long training runs, Dr. Patel has been able to reflect on her patients and look forward to the next great advances in lung cancer prevention and treatment.
Because lung cancer is associated with smoking, many people feel it is “self-inflicted.” This not only causes people to feel guilt and shame, but also leads to less research funding and fewer advances in treatment. In this guest post, Dr. Jyoti Patel talks about how the stigma of lung cancer affects the way patients are treated—both socially and medically.
What would it be like to meet the inventor of the investigational drug that is keeping you alive? Janet Freeman-Daily found out firsthand at the 2014 ASCO Annual Meeting.